JP2007517049A5 - - Google Patents

Download PDF

Info

Publication number
JP2007517049A5
JP2007517049A5 JP2006547469A JP2006547469A JP2007517049A5 JP 2007517049 A5 JP2007517049 A5 JP 2007517049A5 JP 2006547469 A JP2006547469 A JP 2006547469A JP 2006547469 A JP2006547469 A JP 2006547469A JP 2007517049 A5 JP2007517049 A5 JP 2007517049A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
pharmacological substance
pharmacological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006547469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007517049A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/043628 external-priority patent/WO2005065308A2/en
Publication of JP2007517049A publication Critical patent/JP2007517049A/ja
Publication of JP2007517049A5 publication Critical patent/JP2007517049A5/ja
Pending legal-status Critical Current

Links

JP2006547469A 2003-12-29 2004-12-29 再発性病状を治療するための組成物および方法 Pending JP2007517049A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53300303P 2003-12-29 2003-12-29
US62525304P 2004-11-05 2004-11-05
PCT/US2004/043628 WO2005065308A2 (en) 2003-12-29 2004-12-29 Compositions and methods to treat recurrent medical conditions

Publications (2)

Publication Number Publication Date
JP2007517049A JP2007517049A (ja) 2007-06-28
JP2007517049A5 true JP2007517049A5 (cg-RX-API-DMAC7.html) 2008-02-21

Family

ID=34752985

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006547469A Pending JP2007517049A (ja) 2003-12-29 2004-12-29 再発性病状を治療するための組成物および方法

Country Status (8)

Country Link
US (2) US7846913B2 (cg-RX-API-DMAC7.html)
EP (1) EP1703907A4 (cg-RX-API-DMAC7.html)
JP (1) JP2007517049A (cg-RX-API-DMAC7.html)
KR (1) KR20070007276A (cg-RX-API-DMAC7.html)
AU (1) AU2004311869A1 (cg-RX-API-DMAC7.html)
CA (1) CA2592631A1 (cg-RX-API-DMAC7.html)
RU (1) RU2006127475A (cg-RX-API-DMAC7.html)
WO (1) WO2005065308A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
CA2609972C (en) * 2004-03-22 2013-05-14 Apkarian Technologies Llc Method and compositions for treatment of chronic neuropathic pain
US20060084659A1 (en) * 2004-10-19 2006-04-20 Michael Davis Augmentation of psychotherapy with cannabinoid reuptake inhibitors
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
DE102005009241A1 (de) * 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit kontrollierter Bioverfügbarkeit
WO2007018801A1 (en) * 2005-07-28 2007-02-15 Teikoku Pharma Usa, Inc. Gelled donepezil compositions and methods for making and using the same
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
US20100113453A1 (en) * 2007-04-10 2010-05-06 Mcdevitt Jason P Sublingual Formulations of D-Cycloserine and Methods of Using Same
ATE515259T1 (de) * 2007-05-29 2011-07-15 Lek Pharmaceuticals Pharmazeutische zusammensetzung mit eszopiclon
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20100291225A1 (en) * 2008-01-14 2010-11-18 Jubilant Organosys Ltd. Stabilized Sustained Release Composition of Bupropion Hydrochloride and Process For Preparing the Same
US20100204291A1 (en) * 2009-02-12 2010-08-12 Mcdevitt Jason P Method for Facilitating Extinction Training Using D-Cycloserine
US9789093B2 (en) 2011-01-31 2017-10-17 Serotech, Llc Dosage regimen, medication dispensing package and uses thereof for the treatment of major depressive disorder
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
US10583138B2 (en) 2012-07-12 2020-03-10 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
MX336979B (es) * 2011-12-16 2016-02-09 Senosiain S A De C V Lab Combinacion farmaceutica antineuritica y composiciones.
US9877951B2 (en) 2015-02-12 2018-01-30 College Of William And Mary Method for treating dementia
US20170143681A1 (en) 2015-11-02 2017-05-25 Apkarian Technologies Llc Methods and compositions for treating pain
US10485790B1 (en) * 2018-09-13 2019-11-26 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof
US11291654B2 (en) * 2018-09-13 2022-04-05 Syneurx International (Taiwan) Corp. Formulations of cycloserine compounds and applications thereof
WO2025173704A1 (ja) * 2024-02-16 2025-08-21 エフバイタル株式会社 薬剤のスクリーニング方法、および剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5061721A (en) 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
JPH03236315A (ja) * 1989-12-05 1991-10-22 Nippon Oil & Fats Co Ltd 抗精神病薬
US5260324A (en) 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5086072A (en) 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5428069A (en) 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
US6355681B2 (en) 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
US6133281A (en) * 1996-10-24 2000-10-17 Harbor-Ucla Research And Education Institute NMDA receptor blockers in the therapy of urogenital disease
WO1999051252A1 (en) * 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
AU765603C (en) 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
CA2372073A1 (en) * 1999-04-29 2000-11-09 Merck Patent Gesellschaft Mit Beschraenkter Haftung Glycine cleavage system inhibitors as potential antipsychotics
US20010053780A1 (en) * 1999-04-30 2001-12-20 Whitaker John S. Daily treatment for erectile dysfunction using a PDE5 inhibitor
US6333357B1 (en) 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
US20050096396A1 (en) 2002-03-28 2005-05-05 Emory University Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
ATE519485T1 (de) * 2001-03-29 2011-08-15 Michael Davis Akute pharmakologische verstärkung einer psychotherapie mit d-cycloserine
GB0129274D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Novel kit
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
GB0322140D0 (en) * 2003-09-22 2003-10-22 Pfizer Ltd Combinations

Similar Documents

Publication Publication Date Title
Gonda et al. Novel antidepressant drugs: Beyond monoamine targets
JP7226839B2 (ja) ブプロピオンおよびデキストロメトルファンを含む組成物
JP7265990B2 (ja) 神経変性疾患あるいは認知機能障害の予防または治療剤としてのr-ケタミンおよびその誘導体
US10682354B2 (en) Compositions and methods
EA200900491A1 (ru) Применение эстрадиола валерата или 17в-эстрадиола в комбинации с диеногестом для перорального лечения для поддержания и/или повышения полового влечения у особи женского пола
WO2010129864A3 (en) Methods and compositions for studying, imaging, and treating pain
JP2016535786A (ja) ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物および方法
JP2019503365A5 (cg-RX-API-DMAC7.html)
CA3094580C (en) Oral formulations of cytidine analogs and methods of use thereof
RU2006127475A (ru) Композиции и способы лечения рецидивирующих медицинских состояний
WO2004087116A3 (es) Combinación de drogas para la disfunción motora en la enfermedad de parkinson
JP2002505681A (ja) 健常人における気分障害を調節するための組成物
JP2005515964A5 (cg-RX-API-DMAC7.html)
WO2006053049A3 (en) Herbal composition phy906 and its use in chemotherapy
van Praag et al. 5-hydroxytryptophan in combination with clomipramine in “therapy-resistant” depressions
WO2020138491A1 (ja) 神経発達障害の予防または治療剤としてのr-ケタミンおよびその誘導体
NO20082672L (no) Anvendelse av cikletanin og andre fluorpyridiner for behandling av systolisk-dominant hypertensjon, isolert hypertensjon, oket pulstrykk og generell hypertensjon
JP2023531675A5 (cg-RX-API-DMAC7.html)
RU2017127509A (ru) Композиции и способы для улучшенного мышечного метаболизма
CN119215038A (zh) mGluR5拮抗剂用于治疗阿片类物质镇痛耐受性的用途
MX2008015887A (es) Tratamiento de condiciones psicologicas utilizando antagonista m1 de receptor muscarinico.
RU2007132852A (ru) Продукт комбинации о-десметилвенлафаксина и базедоксифена и его применение
WO2021180915A1 (fr) Utilisation de nicotinamide mononucléotide ou de certains de ses dérivés pour la prevention et/ou le traitement d'une douleur dorsale, et compositions correspondantes
CA2528312A1 (en) Methods of managing the symptoms of premenstrual syndrome
HK1214505A1 (zh) 治療方案